

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies.

Florent Malard^{1,2*}, Béatrice Gaugler^{1,2*}, Joel Gozlan^{2,3*}, Lucie Bouquet⁴, Djeneba Fofana^{3,5}, Lama Siblany^{1,2}, Deborah Eshagh², Olivier Adotevi⁴, Caroline Laheurte⁴, Laure Ricard^{1,2}, Rémy Dulery^{1,2}, Nicolas Stocker^{1,2}, Zoe van de Wyngaert^{1,2}, Alexis Genthon^{1,2}, Anne Bannet^{1,2}, Mara Memoli¹, Souhila Ikhlef¹, Simona Sestilli^{1,2}, Anne Vekhof¹, Eolia Brissot^{1,2}, Zora Marjanovitch¹, Yannick Chantran⁶, Nancy Cuervo³, Eric Ballot⁶, Laurence Morand-Joubert^{3,5}, Mohamad Mohty^{1,2#}

¹ APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France

² Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), F-75012 Paris, France

³ APHP, Hôpital Saint Antoine, Department of Virology, Paris, France

⁴ Department of Medical Oncology, University Hospital of Besançon, INSERM, EFS BFC, UMR1098 RIGHT, Université de Bourgogne Franche-Comté, France

⁵ Sorbonne Université Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM UMR S1136

⁶ APHP, Hôpital Saint Antoine, Service d'Immunologie, Paris, France

* These authors contributed equally to this work and should be considered as first authors.


Supplementary file

Supplementary Table 1.

		inhibition		Total
		<30%	>=30%	
Anti-S IgG	<3100	56 (98.2%)	6 (15.0%)	62
	>=3100	1 (1.8%)	34 (85%)	35
	Total	57	40	97

Supplementary Figure 1. Adverse events.

Adverse events after first (A) and second (B) inoculum of BNT162b2 vaccine.



Supplementary Figure 2. T cells response to COVID-19 BNT162b2 vaccine.

T cell response was assessed by IFN- γ ELISPOT at baseline (before first BNT162b2 vaccination, d0) and 2 weeks after the second BNT162b2 vaccination (d42), n=68. T cell response against CMV, EBV, Influenza virus and Tetanus toxoid (CEF/CEFT). T cell response against SARS-CoV-2 spike protein (S), or its receptor binding domain (RBD), or against membrane protein (M). CLL is for chronic lymphocytic leukemia; AL MDS, acute leukemia and myelodysplastic syndrome; MPN, myeloproliferative neoplasm.

